Die Sterblichkeit invasiver Pneumokokkenerkrankungen ist hoch – Tun wir alles, um die Letalität zu senken?

• Literatur

• 1 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79
• 2 Ludwig E, Bonanni P, Rohde G et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21: 57-65
• 3 van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374 (9700): 1543-1556
• 4 Mook-Kanamori BB, Geldhoff M, van der Poll T et al. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24: 557-591
• 5 Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237
• 6 Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368: 1495-1502
• 7 Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365: 855-863
• 8 Pletz MW, Maus U, Krug N et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206
• 9 Moberley SA, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 23 (01) CD000422
• 10 Huss A, Scott P, Stuck AE et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58
• 11 Lee H, Nahm MH, Kim KH. The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis 2010; 10: 60
• 12 Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340: c1004
• 13 de Roux A, Schmöle-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023
• 14 Ständige Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2011. Epid Bull 2011; 30: 275-294
• 15 Bryant KA, Block SL, Baker SA et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125: 866-875
• 16 Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383
• 17 Ständige Impfkommission (STIKO) am Robert Koch-Institut. Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epid Bull 2012; 7: 55-56
• 18 Smith KJ, Wateska AR, Nowalk MP et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307: 804-812
• 19 Schwarz TF, Flamaing J, Rümke HC et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine 2011; 29: 5195-5202
• 20 van der Linden M, Weiß S, Falkenhorst G et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; Jul 4